These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28316003)

  • 21. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).
    Dash C; Gascoigne E; Gillanders K; Gooi H
    PLoS One; 2015; 10(7):e0131565. PubMed ID: 26222441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
    Ballow M
    Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
    Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
    J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
    Rojavin MA; Hubsch A; Lawo JP
    J Clin Immunol; 2016 Apr; 36(3):210-9. PubMed ID: 26910102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates.
    Bauer S; Fadeyi M; Chan S
    J Infus Nurs; 2019; 42(6):297-302. PubMed ID: 31693563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
    Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
    Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
    [No Abstract]   [Full Text] [Related]  

  • 33. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
    Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
    Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.
    Bleasel K; Heddle R; Hissaria P; Stirling R; Stone C; Maher D
    Intern Med J; 2012 Mar; 42(3):252-9. PubMed ID: 22212346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
    Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
    Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
    Church JA; Leibl H; Stein MR; Melamed IR; Rubinstein A; Schneider LC; Wasserman RL; Pavlova BG; Birthistle K; Mancini M; Fritsch S; Patrone L; Moore-Perry K; Ehrlich HJ;
    J Clin Immunol; 2006 Jul; 26(4):388-95. PubMed ID: 16705486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.